Supplementary report of the Kelkar Committec

2933. DR. RATNAKAR PANDEY: SHRI RAJNI RANJAN SAHU:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1385 given in the Rajya Sabha on the 21st November, 1988 and state:

(a) when was the supplementary *report* submitted to Government by Kelkar Committee and whether the same has been examined- and

(b) by when the report will be placed on the Table of the House?

THE MINISTER OF INDUSTRY (SHRi J. VENGAL RAO): (a) and 0>) Kelkar Committee had submitted its supplementary report recently and the same is under examination.

Amount due on Streptomycin

2934. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstar red Question 3110 given in the Rajya Sabha on 7th December, 1987 and state:

(a) what is the position in respect to the difference between the pooled /com mon sale price and the retention price of Streptomycin payable by Synbiotics into the Drug Prices Equalisation Account;

(b) whether any calculation of the amount which is due has been carried out from 1979 and if so, what are the details of the total amount due;

(c) whether any notice has been served to the roirmanv for the recovery of the amount due and if not, by when the' notice would be served;

(d) whether his Ministry collected any amount on account of Streptomycin, and

(e) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) Information to the extent available, would be collected and laid on the Table of the House.

Under utilisation of IDPL capacities

2935. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what is the investment made and capacity established for each Ampicillin, 6APA, Erythromycin Doxycycline, Niacinamide and Griseofulvin by Indian Drugs & Pharmaceuticals Ltd.;

(b) what wa$_s$ the production of these drugs during the last three years and what is the installed capacity;

(c) what are the production fees and other payments made for each of these drugs to the foreign collaborators; and

(d) what are the reasons that these pro. jects are not being implemented and operated at dull rated capacity and what was the nime of the collaborator in each case?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (c) The information is given in the statement attached. *[See* Appendix CXVIII, Annexure No. 125].

(b) The present installed capacity and production during the last 3 years are as under:—

(UNIT M.T.)

Name *of* the Product	Present installed capacity	Production during		
		1985-86	1986-87	1987-88
Ampicillin 6-	35	1.5	2.5	5.7
APA	47	26.6*	1.9*	8.6*
Erythromycin	30	0.2		2.2

1	2	3			
Doxycycline		2.5	8.4	111.67	77.65
Niacinamide		3.00 1			
Griseofulvin					
Saleable					

(d) Production of Ampicillin was restricted to captive requirements. Production of 6-APA was as per market requirements. Production of Doxycycline, Erythromycin, Griseofulvin was not economical and hence not taken up for production. Production of Niacinamide suffered on account of erratic power supply and limited availability of alcohol. The names of collaborators are given in the statement attached. *[See* Appendix CXLVITI, Annexure No. 125.]

Price control on vitamins

2936. SHRI JAGESH DESAI:
SHRI RAOOF VALIULLAH:

Will the Minister of INDUSTRY be pleased to refer to the answer to the Unstarred Question 1430 given in the Rajya Sabha on 2lst November, 1988 and state:

(a) whether it is a fact that Kelkar Committee recommended price control on bulk vitamins; and

(b) if so, on what basis only Vitamin 1 Vitamin C have been brought under price control and not Vitamin B 1 Vitamin B_2 and Vitamin B_6

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Pending detailed examination of the supplementary report submitted by the Kelkar Committee, Vitamin A and Vitamin C have been brought under price control on the basis of their importance and usage pattern etc.

Production of bulk drugs by IDPL

2937. SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the' answer to Starred Question 149 given in the Rajya Sabha on 21st November, 1988 and state:

(a) what are the names of price controlled bulk drugs for which IDPL has been licensed to produce;

(b) what is the capacity sanctioned for each and w'hat was the production of each of these drugs during the last four years, year-wise;

(c) what is the value of plant and machinery installed for the production ot each drug;

(d) whether IDPL paid any technology fee on any of these drugs; and

(e) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Names of bulk drugs are given in the enclosed statement (see below).

(b) to (e) Since the number of drugs are numerous, time and labour involved in collection and compilation of data will not be commensurate with the results likely to be achieved.

Statement

1. Streptomycin
2. Isoniazid
3. Thiacetazone
4, Ethambutol
5. Sodium PAS
6, Pyrazinamide
7. Tetracycline Hcl.
8. Sodium Sulphacetamide
9. Chloroquine
10 Paracetamol